These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 11067646)

  • 1. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.
    Lindström E; Bingefors K
    Pharmacoeconomics; 2000 Aug; 18(2):106-24. PubMed ID: 11067646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
    Möller HJ
    Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of noncompliance in patients with schizophrenia.
    Perkins DO
    J Clin Psychiatry; 2002 Dec; 63(12):1121-8. PubMed ID: 12523871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
    Haycox A
    Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New generation antipsychotic drugs and compliance behaviour.
    Voruganti LP; Baker LK; Awad AG
    Curr Opin Psychiatry; 2008 Mar; 21(2):133-9. PubMed ID: 18332660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
    Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
    J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH; Chouinard G; Margolese HC
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic review of compliance with medication therapy in the treatment of schizophrenia.
    Thieda P; Beard S; Richter A; Kane J
    Psychiatr Serv; 2003 Apr; 54(4):508-16. PubMed ID: 12663838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.